Univariate analysis of OS
| Parameter . | Death/N . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Age, y | ||||
| <30 | 2/19 | 1.00 | ||
| 30-35 | 13/38 | 2.04 | 0.66-8.86 | .26 |
| >35 | 36/121 | 1.89 | 0.68-7.85 | .29 |
| MGUS history | ||||
| No | 46/160 | 1.00 | ||
| Yes | 1/12 | 0.27 | 0.01-1.22 | .19 |
| Isotype | ||||
| IgG | 36/110 | 1.00 | ||
| IgA | 7/23 | 1.19 | 0.54-2.37 | .63 |
| MM light chain | ||||
| No | 42/133 | 1.00 | ||
| Yes | 8/43 | 0.59 | 0.27-1.15 | .15 |
| Bone lesions | ||||
| No | 6/36 | 1.00 | ||
| Yes | 41/133 | 3.15 | 1.37-9.13 | .01* |
| Hypercalcemia | ||||
| ≤2.75 mmol/L | 41/146 | 1.00 | ||
| >2.75 mmol/L | 7/18 | 1.82 | 0.79-3.66 | .12 |
| GFR, mL/min | ||||
| ≥60 | 38/141 | 1.00 | ||
| <60 | 10/28 | 1.57 | 0.74-3.02 | .20 |
| Proteinuria >1g/L | ||||
| No | 25/95 | 1.00 | ||
| Yes | 8/29 | 1.13 | 0.52-2.27 | .73 |
| Anemia | ||||
| No | 26/110 | 1.00 | ||
| Yes | 22/59 | 2.07 | 1.19-3.60 | .009* |
| ISS | ||||
| 1 | 18/87 | 1.00 | ||
| 2 | 13/40 | 1.84 | 0.89-3.74 | .09* |
| 3 | 12/30 | 2.63 | 1.25-5.41 | .009* |
| High-risk cytogenetics | ||||
| No | 37/152 | 1.00 | ||
| Yes | 14/31 | 2.75 | 1.53-4.93 | <.001* |
| First-line treatment | ||||
| VAD/DCEP | 24/49 | 1.00 | ||
| VD/VCD/PAD | 15/53 | 0.85 | 0.43-1.62 | .61 |
| VTD/VRD | 11/73 | 0.72 | 0.33-1.48 | .37 |
| Parameter . | Death/N . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Age, y | ||||
| <30 | 2/19 | 1.00 | ||
| 30-35 | 13/38 | 2.04 | 0.66-8.86 | .26 |
| >35 | 36/121 | 1.89 | 0.68-7.85 | .29 |
| MGUS history | ||||
| No | 46/160 | 1.00 | ||
| Yes | 1/12 | 0.27 | 0.01-1.22 | .19 |
| Isotype | ||||
| IgG | 36/110 | 1.00 | ||
| IgA | 7/23 | 1.19 | 0.54-2.37 | .63 |
| MM light chain | ||||
| No | 42/133 | 1.00 | ||
| Yes | 8/43 | 0.59 | 0.27-1.15 | .15 |
| Bone lesions | ||||
| No | 6/36 | 1.00 | ||
| Yes | 41/133 | 3.15 | 1.37-9.13 | .01* |
| Hypercalcemia | ||||
| ≤2.75 mmol/L | 41/146 | 1.00 | ||
| >2.75 mmol/L | 7/18 | 1.82 | 0.79-3.66 | .12 |
| GFR, mL/min | ||||
| ≥60 | 38/141 | 1.00 | ||
| <60 | 10/28 | 1.57 | 0.74-3.02 | .20 |
| Proteinuria >1g/L | ||||
| No | 25/95 | 1.00 | ||
| Yes | 8/29 | 1.13 | 0.52-2.27 | .73 |
| Anemia | ||||
| No | 26/110 | 1.00 | ||
| Yes | 22/59 | 2.07 | 1.19-3.60 | .009* |
| ISS | ||||
| 1 | 18/87 | 1.00 | ||
| 2 | 13/40 | 1.84 | 0.89-3.74 | .09* |
| 3 | 12/30 | 2.63 | 1.25-5.41 | .009* |
| High-risk cytogenetics | ||||
| No | 37/152 | 1.00 | ||
| Yes | 14/31 | 2.75 | 1.53-4.93 | <.001* |
| First-line treatment | ||||
| VAD/DCEP | 24/49 | 1.00 | ||
| VD/VCD/PAD | 15/53 | 0.85 | 0.43-1.62 | .61 |
| VTD/VRD | 11/73 | 0.72 | 0.33-1.48 | .37 |
'Death/N' represents the number of deaths per number of patients.
DCEP, cyclophosphamide + etoposide + doxorubicin + prednisone; GFR, glomerular filtration rate; IgA, immunoglobulin A; MGUS, monoclonal gammopathy of unknown significance; PAD, bortezomib + Adriamycin + dexamethasone; VAD, vincristine + Adriamycin + dexamethasone; VCD, bortezomib + cyclophosphamide + dexamethasone; VD, bortezomib + dexamethasone; VRD, bortezomib + lenalidomide + dexamethasone; VTD, bortezomib + thalidomide + dexamethasone.
Parameters were selected for multivariate analysis.